Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome
10.1093/rheumatology/37.11.1229 · doi-reference
International consensus statement on preliminary classification criteria for define antiphospholipid syndrome: report of an international workshop
10.1002/1529-0131(199907)42:7<1309::aid-anr1>3.0.co;2-f · doi-reference
Henoch-Schonlein Purpura and stroke: antiphosphatidylethanolamine antibody (aPE) in CSF and serum
10.1212/wnl.55.9.1379 · doi-reference
Qualitative and quantitative studies of autoantibodies to phospholipids in diabetes mellitus
10.1046/j.1365-2249.1999.01014.x · doi-reference
Antiphospholipid antibodies, thrombosis and atherosclerosis in systemic lupus erythematosus: a unifying ‘membrane stress syndrome’ hypothesis
10.1177/096120339400300503 · doi-reference
Antiphospholipid antibodies in alcoholic liver disease
10.1002/hep.1840200614 · doi-reference
Antiphospholipid antibodies in sickle cell disease
10.1002/ajh.2830420409 · doi-reference
Increased incidence of antiphospholipid antibodies in left ventricular assist system recipients
10.1016/s0003-4975(99)00458-0 · doi-reference
Antiphospholipid antibodies in left-ventricular assist system recipients after exposure to topical bovine thrombin
10.1016/s0041-1345(98)01479-1 · doi-reference
Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation
10.1016/0049-3848(96)00165-x · doi-reference
Antiphospholipid antibodies are a risk factor for early renal allograft failure: isolation of antiphospholipid antibodies from a thrombosed renal allograft
10.1016/s0041-1345(98)01629-7 · doi-reference
The pre-conditioning incidence of antiphospholipid antibodies is not significantly increased in patients with bone marrow transplant-related organ dysfunction
10.1038/sj.bmt.1701411 · doi-reference
Risk of early renal allograft failure is increased for patients with antiphospholipid antibodies
10.1111/j.1432-2277.2000.tb02122.x · doi-reference
The evolution, evaluation and interpretation of antiphospholipid antibody assays
10.1016/0197-1859(95)80013-1 · doi-reference
Antiphospholipid antibodies in heart transplant recipients
10.1002/clc.4960181009 · doi-reference
Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients
10.1097/00007890-199901150-00015 · doi-reference
Antiphospholipid antibodies are a risk factor for early renal allograft failure
10.1097/00007890-199907270-00014 · doi-reference
Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss
10.1055/s-0037-1614001 · doi-reference
Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss?
10.1177/096120339600500515 · doi-reference
Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses
10.1016/s0015-0282(99)00119-3 · doi-reference
Antiphospholipid antibodies associated with implantation failure after IVF/ET
10.1023/a:1022588903620 · doi-reference
Antibodies to B2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study
10.1016/s0015-0282(98)00312-4 · doi-reference
Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome
10.1016/s0029-7844(97)00065-3 · doi-reference
Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies
10.1016/s0015-0282(16)58565-3 · doi-reference
Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Colombian women with recurrent spontaneous abortions
10.1016/0165-0378(94)00906-n · doi-reference
Autoantibodies in women with primary recurrent spontaneous abortion of unknown etiology
10.1016/0165-0378(92)90003-m · doi-reference
Recurrent abortion and moderate or strong antiphospholipid antibody production
10.1016/s0020-7292(98)00099-x · doi-reference
